Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2014 (2014), Article ID 687257, 8 pages
http://dx.doi.org/10.1155/2014/687257
Clinical Study

Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement

Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan

Received 13 February 2014; Revised 22 March 2014; Accepted 24 March 2014; Published 16 April 2014

Academic Editor: Gerassimos Mantzaris

Copyright © 2014 Tsutomu Mizoshita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. H. van Deventer, “Tumour necrosis factor and Crohn's disease,” Gut, vol. 40, no. 4, pp. 443–448, 1997. View at Google Scholar · View at Scopus
  2. W. J. Sandborn, P. Rutgeerts, R. Enns et al., “Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial,” Annals of Internal Medicine, vol. 146, no. 12, pp. 829–838, 2007. View at Google Scholar · View at Scopus
  3. G. R. D'Haens, R. Panaccione, P. D. R. Higgins et al., “The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response,” The American Journal of Gastroenterology, vol. 106, no. 2, pp. 199–213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Mizoshita, S. Tanida, S. Kusumoto et al., “Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia,” Clinical Journal of Gastroenterology, vol. 5, no. 4, pp. 302–306, 2012. View at Publisher · View at Google Scholar
  5. S. B. Hanauer, W. J. Sandborn, P. Rutgeerts et al., “Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial,” Gastroenterology, vol. 130, no. 2, pp. 323–332, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. W. J. Sandborn, S. B. Hanauer, P. Rutgeerts et al., “Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial,” Gut, vol. 56, no. 9, pp. 1232–1239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Watanabe, T. Hibi, K. G. Lomax et al., “Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease,” Journal of Crohn's and Colitis, vol. 6, no. 2, pp. 160–173, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J.-F. Colombel, W. J. Sandborn, P. Rutgeerts et al., “Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial,” Gastroenterology, vol. 132, no. 1, pp. 52–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Schreiber, W. Reinisch, J. F. Colombel et al., “Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease,” Journal of Crohn's and Colitis, vol. 7, no. 3, pp. 213–221, 2013. View at Publisher · View at Google Scholar
  10. M.-P. Buisine, P. Desreumaux, E. Leteurtre et al., “Mucin gene expression in intestinal epithelial cells in Crohn's disease,” Gut, vol. 49, no. 4, pp. 544–551, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Shaoul, Y. Okada, E. Cutz, and M. A. Marcon, “Colonic expression of MUC2, MUC5AC, and TFF1 in inflammatory bowel disease in children,” Journal of Pediatric Gastroenterology and Nutrition, vol. 38, no. 5, pp. 488–493, 2004. View at Google Scholar · View at Scopus
  12. N. Tatsumi, R. Kushima, M. Vieth et al., “Cytokeratin 7/20 and mucin core protein expression in ulcerative colitis-associated colorectal neoplasms,” Virchows Archiv, vol. 448, no. 6, pp. 756–762, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Takeda, S. Ban, H. Iseki, Y. Otani, and I. Koyama, “Gastric differentiation markers expression is potentially useful for the detection of ulcerative colitis-associated dysplasias,” Hepato-Gastroenterology, vol. 56, no. 89, pp. 252–253, 2009. View at Google Scholar · View at Scopus
  14. P. Borralho, A. Vieira, J. Freitas, P. Chaves, and J. Soares, “Aberrant gastric apomucin expression in ulcerative colitis and associated neoplasia,” Journal of Crohn's and Colitis, vol. 1, no. 1, pp. 35–40, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Mizoshita, S. Tanida, H. Tsukamoto et al., “Colon mucosa exhibits loss of ectopic MUC5AC expression in patients with ulcerative colitis treated with oral tacrolimus,” ISRN Gastroenterology, vol. 2013, Article ID 304894, 7 pages, 2013. View at Publisher · View at Google Scholar
  16. Y. Kaneko, T. Nakamura, M. Hayama, N. Hosaka, T. Akamatsu, and H. Ota, “Altered expression of CDX-2, PDX-1 and mucin core proteins in “ulcer-associated cell lineage (UACL)” in Crohn's disease,” Journal of Molecular Histology, vol. 39, no. 2, pp. 161–168, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. W. R. Best, J. M. Becktel, J. W. Singleton, and F. Kern Jr., “Development of a Crohn's disease activity index. National cooperative Crohn's disease study,” Gastroenterology, vol. 70, no. 3, pp. 439–444, 1976. View at Google Scholar · View at Scopus
  18. F. Ueno, T. Matsui, T. Matsumoto, K. Matsuoka, M. Watanabe, and T. Hibi, “Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan,” Journal of Gastroenterology, vol. 48, no. 1, pp. 31–72, 2013. View at Publisher · View at Google Scholar
  19. J. Y. Mary and R. Modigliani, “Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID),” Gut, vol. 30, no. 7, pp. 983–989, 1989. View at Publisher · View at Google Scholar
  20. P. Rutgeerts, G. van Assche, W. J. Sandborn et al., “Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial,” Gastroenterology, vol. 142, no. 5, pp. 1102.e2–1111.e2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Mizoshita, T. Tsukamoto, H. Nakanishi et al., “Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis,” Journal of Cancer Research and Clinical Oncology, vol. 129, no. 12, pp. 727–734, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Mizoshita, T. Tsukamoto, K.-I. Inada et al., “Loss of MUC2 expression correlates with progression along the adenoma-carcinoma sequence pathway as well as de novo carcinogenesis in the colon,” Histology and Histopathology, vol. 22, no. 3, pp. 251–260, 2007. View at Google Scholar · View at Scopus
  23. M.-E. Forgue-Lafitte, B. Fabiani, P. P. Levy, N. Maurin, J.-F. Flejou, and J. Bara, “Abnormal expression of M1/MUC5AC mucin in distal colon of patients with diverticulitis, ulcerative colitis and cancer,” International Journal of Cancer, vol. 121, no. 7, pp. 1543–1549, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. X. G. Shao, I. F. Ueki, and J. A. Nadel, “Tumor necrosis factor α-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 20, pp. 11618–11623, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. K. S. Song, W.-J. Lee, K. C. chung et al., “Interleukin-1β and tumor necrosis factor-α induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells,” The Journal of Biological Chemistry, vol. 278, no. 26, pp. 23243–23250, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. B. M. Fischer, L. G. Rochelle, J. A. Voynow, N. J. Akley, and K. B. Adler, “Tumor necrosis factor-α stimulates mucin secretion and cyclic GMP production by guinea pig tracheal epithelial cells in vitro,” American Journal of Respiratory Cell and Molecular Biology, vol. 20, no. 3, pp. 413–422, 1999. View at Google Scholar · View at Scopus
  27. J. Ryu, H. J. Lee, S. H. Park et al., “Effect of prunetin on TNF-α-induced MUC5AC mucin gene expression, production, degradation of IκB and translocation of NF-κB p65 in human airway epithelial cells,” Tuberculosis and Respiratory Diseases, vol. 75, no. 5, pp. 205–209, 2013. View at Publisher · View at Google Scholar
  28. M. A. Sikder, H. J. Lee, M. Z. Mia et al., “Inhibition of TNF-α-induced MUC5AC mucin gene expression and production by wogonin through the inactivation of NF-κB signaling in airway epithelial cells,” Phytotherapy Research, vol. 28, no. 1, pp. 62–68, 2014. View at Publisher · View at Google Scholar
  29. T. Tsukamoto, K. Inada, H. Tanaka et al., “Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia,” Journal of Cancer Research and Clinical Oncology, vol. 130, no. 3, pp. 135–145, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Tsukamoto, T. Mizoshita, M. Mihara et al., “Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed phenotypes,” Histopathology, vol. 46, no. 6, pp. 649–658, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Mori, H. Kataoka, Y. Miura et al., “Subcellular localization of ATBF1 regulates MUC5AC transcription in gastric cancer,” International Journal of Cancer, vol. 121, no. 2, pp. 241–247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Rutgeerts, S. Vermeire, and G. Van Assche, “Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?” Gut, vol. 56, no. 4, pp. 453–455, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. G. R. D'Haens, R. Fedorak, M. Lémann et al., “Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease,” Inflammatory Bowel Diseases, vol. 15, no. 10, pp. 1599–1604, 2009. View at Publisher · View at Google Scholar · View at Scopus